Hydroxyurea in Pediatric Patients With Sickle Cell Disease: What Nurses Need to Know

Area of Science:

• Hematology
• Genetics
• Pediatrics

Background:

• Sickle cell disease (SCD) is an inherited blood disorder causing red blood cell sickling, leading to vaso-occlusion and organ damage.
• Hydroxyurea has demonstrated efficacy in managing SCD and preventing associated complications.
• Previous guidelines recommended hydroxyurea based on clinical severity, primarily for older patients with frequent complications.

Purpose of the Study:

• To outline the updated 2014 National Heart, Lung, and Blood Institute guidelines for hydroxyurea treatment in SCD.
• To highlight the shift in recommendation towards earlier and universal use of hydroxyurea in pediatric SCD populations.
• To emphasize the role of healthcare professionals, particularly nurses, in patient education and treatment adherence.

Main Methods:

• Review and analysis of the 2014 National Heart, Lung, and Blood Institute guidelines for SCD management.
• Comparison of the 2014 guidelines with the previous 2002 recommendations regarding hydroxyurea use.
• Identification of key changes in treatment eligibility criteria.

Main Results:

• The 2014 guidelines recommend hydroxyurea for infants (9 months+), children, and adolescents with SCD-SS or SCD-Sβ(0) thalassemia irrespective of clinical severity.
• This represents a significant expansion from the 2002 guidelines, which targeted only those with severe symptoms or frequent events.
• The updated recommendation aims for broader application of hydroxyurea to mitigate long-term SCD effects.

Conclusions:

• Universal hydroxyurea treatment is recommended for pediatric patients with SCD-SS or SCD-Sβ(0) thalassemia starting at 9 months of age.
• The updated guidelines signify a proactive approach to SCD management, emphasizing early intervention.
• Nurses are crucial in educating families and ensuring compliance, thereby improving long-term health outcomes for individuals with SCD.